AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03095989 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: The structure of the protocol incorporates key features of Langer's mindfulness theory. Many of the tasks and exercises have demonstrated increased mindfulness in the general population and have been modified to incorporate ALS-specific exercises that make sense from patients and caregivers' points of view. The intervention provides easily understood multimedia (video and written) presentations of the framework of mindfulness and the aims of the planned tasks. The general structure of the protocol mixes different mindfulness elements; for every week there is a specific topic examined in depth. These topics are: Attention to variability; Positive and negative events; Unpredictability; Sense Making; and Novelty seeking / novelty producing. The overall duration of the protocol is 5 weeks.
Study NCT04170192 — intervention group
Intervention type: PROCEDURE
Intervention: Cord Blood Stem Cell Transplantation
Description: Unrelated cord blood stem cell selection; Reduced intensity conditioning regime; GVHD prevention; Infection prevention.
Study NCT00755586 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mononuclear cell injection: 4 * 10e8 cells
Description: 350 ml bone marrow will be aspirated from the posterior iliac crest under general anesthesia in combination with a muscle tendon transposition surgery. Next, the patients will receive a bone marrow derived mononuclear cell injection of 4 \* 10e8 cells in the m. biceps brachii.
Study NCT00755586 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mononuclear cell injection: 8 * 10e8 cells
Description: 650 ml bone marrow will be aspirated from the posterior iliac crest under general anesthesia in combination with a muscle tendon transposition surgery. Next, the patients will receive a bone marrow derived mononuclear cell injection of 8 \* 10e8 cells in the m. biceps brachii.
Study NCT00755586 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: No mononuclear cell injection
Description: Patients will receive a muscle tendon transposition surgery without bone marrow aspiration or mononuclear cell injection.
Study NCT05446415 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Analyze basal expression incretin for immunolabeling and mRNA expression glucagon-like secretion peptide-1 (GLP-1) and peptide YY (PYY 3-36) incretins by L cells.
Description: Preoperative and postoperative
Study NCT02948985 — intervention group
Intervention type: OTHER
Intervention: treated with FOLFIRI±cetuximab
Description: Peripheral blood samples of 10 mL were collected from the patients for CTCs analysis and tumor marker in every cycle D0 and D8. Tumor response evaluation will be performed after four cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastatic organ, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.The correlation of the RAS status on CTCs and the mutant gene in ctDNA to the therapeutic response will be evaluated.
Study NCT04695301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation protocol through a digital platform
Description: During 3 months the patients will participate in a rehabilitation program through a digital platform
Study NCT00560833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esmirtazapine
Study NCT00560833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04533841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Description: Pt will receive misoprostol for labor induction then after 30 minutes will receive ether propranolol or misoprostol
Study NCT04533841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Pt will receive misoprostol for labor induction then after 30 minutes will receive ether propranolol or misoprostol
Study NCT04533841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT04533841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Propranolol
Study NCT03644979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skydiving
Description: Tandem skydiving (with an experienced instructor)
Study NCT04793321 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Baby carrier
Description: * It is made in china.~* It is made of Cotton-Polyester.~* It has 3 belts - 2 shoulder belts and one waist belt for superior lumbar support. Shoulder straps are padded and adjustable for the parent's comfort. It has webbing straps for shoulder and waist strap adjustment.~* It is suitable for newborn to 12-months baby~* It is available online at babyshopstores https://www.babyshopstores.com/
Study NCT04793321 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Biodex Balance System
Description: * The Biodex Balance System SD (The Biodex Balance System SD Model 945-300, 115 VAC, Shirley, NY, USA) is used to assess the balance in this study.~* It is an objective device that measures dynamic postural stability. It uses a circular platform that allows up to 20˚of of platform tilt in a 360˚ range of motion.~* The measures of postural stability score for BBS are the Overall Stability Index (OSI), Medial-Lateral Stability Index (MLSI), and Anterior-Posterior Stability Index (APSI). These indices are standard deviations that assess the path of sway around the zero point from the center of the platform and are measured in degrees. A high score in these stability indices indicates poor balance.
Study NCT04793321 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Infant mannequin
Description: The mannequin infant has 3 Kg which corresponds to the infant's age from birth until 1month. This weight is selected as it corresponds to the age at which the infants are frequently carried by the mother .
Study NCT04793321 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Biodex gait trainer 2 TM
Description: Gait Trainer 2™ ( model number:950-385, 115 VAC 50/60 Hz, made in the USA) is used for participants to walk on as walking is one of the most common daily life activities. because caregivers commonly walk while carrying their infants as it has a calming effect on crying infants~It consists of :~* Display: Use Audio and Visual Biofeedback - real-time biofeedback prompts patients into a proper gait pattern.~* Heart Rate Monitoring~* Handrail~* Open Platform
Study NCT02359721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tablet clarithromycin 500 mg (Clarino-500) orally
Description: orally
Study NCT03900936 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological tests
Description: This study is not an intervention as such. We are simply comparing the scores of MCI patients who subsequently went on to develop dementia vs those who did not.
Study NCT01194141 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: aerobic exercise training, 45-60 minutes, 3x/week, 12 weeks (3-months)
Study NCT02717793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength testing
Description: isometric muscle strength~1RM measurement of muscle strength
Study NCT02467777 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bair Hugger
Study NCT02467777 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VitaHeat
Study NCT00893659 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: wheat bread with beta-glucan
Description: 3 g beta-glucan in approximately 200 g of wheat bread per day for 3 months
Study NCT00893659 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: wheat bread without beta-glucan
Description: Approximately 200 g of wheat bread (without beta-glucan supplementation) per day for 3 months
Study NCT04497701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF group
Description: Patients received a single dose of 100 ug/kg of PEG-rhG-CSF（Jinyouli®）, on the basis of actual body weight. Peg-rhG-CSF can be used prophylactically only when the interval between two chemotherapy regimens is no less than 12 days.
Study NCT04497701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhG-CSF group
Description: Patients received 5μg/kg/d of rhG-CSF, on the basis of actual body weight.
Study NCT03510481 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: PfSPZ Vaccine is Radiation attenuated, aseptic, purified, vialed, cryopreserved, NF54 P. falciparum sporozoites produced by Sanaria, Inc.
Study NCT03510481 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Clear liquid indistinguishable from the study product will be used as a placebo rather than a comparator vaccine.
Study NCT03510481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artemether 20mg/lumefantrine 120mg (AL)
Description: Licensed antimalarial in the US and Mali for use for uncomplicated malaria.
Study NCT03510481 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: artemether 20mg/lumefantrine 120mg (AL)
Description: Licensed antimalarial in the US and Mali for use for uncomplicated malaria.
Study NCT01842789 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Acessa Procedure
Description: Acessa Procedure
Study NCT00949026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus (Torisel)
Description: Dose de-escalation dependent on microdialysis results
Study NCT01081977 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early Cord Clamping
Description: Early Umbilical Cord Clamping (Clamping of Umbilical Cord within 30 seconds of shoulder delivery of neonate)
Study NCT01081977 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed Cord Clamping
Description: Delayed Umbilical Cord Clamping (Clamping Umbilical Cord after 2 minutes of shoulder delivery of neonate
Study NCT03588572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine hydrochloride capsules
Description: The patients in venlafaxine group begin to take the venlafaxine hydrochloride capsules after the first visitation(the first day after randomization), each containing venlafaxine 75mg, 1 capsule per day, until 4 weeks after randomization
Study NCT00450424 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: counseling intervention
Description: Participants in the Counseling intervention will meet with the study health educator who will provide the participant with the standard MSI informed consent form and provide a brief, standardized explanation of the MSI test. At that time, the participant can ask any questions s/he wishes to ask. The patients will either sign (or not sign, if they do not consent to have the test, or wish to think further about the decision) after this discussion. Participants who have further questions will be referred to either the attending physician or the genetics counselor at each hospital site.
Study NCT00450424 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: CD-ROM intervention
Description: Participants who are randomized to the CD-ROM condition will complete the baseline interview and then meet with the health educator who will provide the participant with the standard MSI consent form and provide a brief, standardized explanation of the MSI test. At that time, the participant can ask any questions s/he wishes to ask. Next, the participant will be provided with the CD-ROM to view on a laptop computer in the clinic. Participants will also be given a copy of the CD-ROM to take home and keep for future reference. The CD-ROM patients will sign (or not sign, if they do not consent or wish to think further about the decision) the consent form after this discussion.
Study NCT00850616 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V526
Description: 0.5 mL intramuscular injections of MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4 and Week 26.
Study NCT00850616 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo to V526
Description: 0.5 mL intramuscular injections of placebo to MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4, and Week 26.
Study NCT02863991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: 375 mg or 625 mg ONC201
Study NCT02863991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg dexamethasone
Study NCT00149773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy
Study NCT00951717 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral education intervention
Description: One education session with a social worker while at the hospital, provision of an educational pamphlet and summary sheet for partner, a needs assessment by the social worker 2 weeks after hospital discharge, and additional patient education and reinforcement of self-management skills, as needed
Study NCT00089310 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: technetium-99
Description: 0.25 mCi in 4 equal doses
Study NCT04647279 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dual-emission X-ray Absorptiometry
Description: The recruiters were divided into osteoporosis, osteopenia and normal by dual emission X-ray absorptiometry.
Study NCT01608776 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MIST Therapy
Description: The MIST Therapy System is used as a non-contact method of delivering ultrasound to treat chronic wounds.
Study NCT01608776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SOC - Standard of Care
Description: Standard of Care includes wound cleansing and debridement as needed, moist wound healing dressings, and offloading
Study NCT00567346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oralgen
Description: Patients will receive drops of grass pollen immunotherapy sublingually
Study NCT00567346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: grass pollen extract
Description: Patients will receive matching placebo sublingually
Study NCT01508325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: Subjects will receive bisoprolol fumarate (Concor®) at a dose of 5 milligram (mg) once daily orally as sustained release (SR) tablets for a period of 4 weeks. The dose of bisoprolol will be escalated to 7.5 mg orally once daily for next 4 weeks (Weeks 4 to 8) and to 10 mg orally once daily for the next 4 weeks (Weeks 8 to 12), if clinic systolic blood pressure (SBP) was greater than or equal to (>=) 140 millimeters of mercury (mmHg) and/or diastolic blood pressure (DBP) was >=90 mmHg measured every 4 weeks.
Study NCT01508325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Subjects will receive metoprolol succinate (Betaloc SR) at a dose of 47.5 mg once daily orally as SR tablets for a period of 4 weeks. The dose of metoprolol will be escalated to 71.25 mg orally once daily for next 4 weeks (Weeks 4 to 8) and to 95 mg orally once daily for the next 4 weeks (Weeks 8 to 12) if clinic SBP was >=140 mmHg and/or DBP was >=90 mmHg measured every 4 weeks.
Study NCT02061709 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ragweed-SPIRE
Study NCT02266784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Study NCT02266784 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Transdermal nicotine skin patches (i.e. Habitrol)
Study NCT02266784 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Supportive Counseling
Study NCT04204109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interprofessional case-based learning
Description: The trial is an educational intervention where groups of healthcare professionals receive the same case-based learning: one group receives case-based learning with healthcare professionals of various professional backgrounds (experimental) versus another group receiving case-based learning with healthcare professionals exclusively of the same professional background (control).~The educational intervention consists of a case that is developed for the purpose of the intervention.~The participants in the experimental group will be randomised into six teams who will receive interprofessional case-based learning. The experimental group will be made up of healthcare professionals from various groups. The participants in the control group will be randomised in groups of one profession
Study NCT04204109 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interprofessional case-based learning
Description: The trial is an educational intervention where groups of healthcare professionals receive the same case-based learning: one group receives case-based learning with healthcare professionals of various professional backgrounds (experimental) versus another group receiving case-based learning with healthcare professionals exclusively of the same professional background (control).~The educational intervention consists of a case that is developed for the purpose of the intervention.~The participants in the experimental group will be randomised into six teams who will receive interprofessional case-based learning. The experimental group will be made up of healthcare professionals from various groups. The participants in the control group will be randomised in groups of one profession
Study NCT01648699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osmotic Release Oral System (OROS) hydromorphone
Description: OROS Hydromorphone will be administered as either 8, 12, 16, 20, 24, 32, 36 or 40 mg oral tablet once daily in the morning. For all participants, 24-hour stable opioid dose (of either morphine or oxycodone) will be converted to a single daily dose of OROS hydromorphone using standard equi-analgesic ratios and dose will be increased if needed, but not more than 40 mg and not more frequently than every two days. The study drug will be administered up to 28 days.
Study NCT06585189 — intervention group
Intervention type: DRUG
Intervention: Pembrolizumab
Study NCT02061709 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT06585189 — intervention group
Intervention type: DRUG
Intervention: Pemetrexed
Study NCT01831518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT Implant
Study NCT01831518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body Surface ECG Mapping
Study NCT02805920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: comparison of different volumes-dosages of 0.25% Bupivacaine
Study NCT02640664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
Study NCT01683318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermal Pulsation therapy
Study NCT02170220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Vortioxetine tablets
Study NCT03678610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Doing ICSI I a medium supplemented with Ionomycin and Latrunculin A
Description: Ionomycin and Latrunculin A would activate oocyte during ICSI along with cytoskeleton stabilization for a favourable outcomes
Study NCT02241200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA3880
Study NCT04242940 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitting of Ponto 4
Description: Bone-anchored hearing systems (BAHS) use the body's natural ability to transfer sound through bone conduction. The sound processor picks up sound and converts it into vibrations that are transferred through the skull bone to the inner ear (cochlea). Thus, for patients with conductive or mixed hearing losses, patients with lasting hearing loss following a middle ear disease or malformations (such as microtia), the vibrations are bypassing the conductive problem in the ear canal or middle ear. The intervention in this study is audiologically fitting one/two bone-anchored sound processors (Ponto 4) to patients that are already implanted with abutments.
Study NCT04377204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: marcaine bupivacaine
Description: This drug is already FDA approved and used for the indication as a local anesthetic. The study herein would like to examine the pain outcomes of enrolled patients who will either have lidocaine alone OR lidocaine+bupivacaine combination locally prior to rhinoplasty surgery.
Study NCT04377204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: This drug is already FDA approved and used for the indication as a local anesthetic. The study herein would like to examine the pain outcomes of enrolled patients who will either have lidocaine alone OR lidocaine+bupivacaine combination locally prior to rhinoplasty surgery.
Study NCT00997841 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Point-of-Care versus conventional coagulation management
Description: Patients are randomized to receive either point-of-care based or conventional coagulation measurements based coagulation therapy in the case of increased perioperative bleeding tendency
Study NCT00746603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: All patients will start at 10mg of simvastatin, and then, based on results of interim evaluation escalated to 20mg and then 40. Patients will stay on maximally tolerated dose of drug until the end of the study at 26 weeks.
Study NCT02069600 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure
Description: CPAP applies a positive pressure into the airway to avoid its collapse during sleep.~The pressure used in each patient is calculate by an auto CPAP device during 3 months. This device calculate the pressure that avoid 95% of sleep-disordered breathing